Loading patent…
OwnerYuzhuo Wang, Hui Xue +4inventors
InventorsYuzhuo Wang, Hui Xue, Sze Ue Luk, Peter Wilhelm Gout, Martin E. Gleave, Colin C. Collins
Estimating the term…
Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).
A method of treating cancer, the method comprising administering to a subject a dual-targeting antisense oligonucleotide (dASO) consisting of SEQ ID NO:1 or SEQ ID NO:2.
A dual-targeting antisense oligonucleotide (dASO), wherein the oligonucleotide consists of a sequence selected from the following:
A pharmaceutical composition, the composition comprising (a) dual-targeting antisense oligonucleotide (dASO) consisting of SEQ ID NO:1or SEQ ID NO:2 wherein the dASO comprises a modification selected from a modified internucleoside linkage, a modified sugar moiety, a 2′MOE gapmer modification and a modified nucleobase;
A commercial package, comprising:
Dependencies are inferred from the claim text.